Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
1998-01-07
2003-10-07
Smith, Lynette R. F. (Department: 1645)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C514S04400A, C435S007320, C435S192000, C424S234100, C424S093200
Reexamination Certificate
active
06630582
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to protective Helicobacter antigens, especially
H. pylori
antigens, and to the use of these antigens for the treatment and prevention of gastroduodenal disease associated with
H. pylori
infection in humans.
BACKGROUND OF THE INVENTION
Helicobacter pylori
is a bacterium that infects the stomach lining (or gastric mucosa) of perhaps half the world's population. Spiral organisms were first microscopically observed in human gastric mucosa in 1906. However,
H. pylori
was not successfully cultured until 1982. Infection with the organism is usually chronic, and results in continuing inflammation of the gastric mucosa. The infection is often asymptomatic. However, in association with other cofactors, a proportion of infected people go on to develop sequelae including peptic ulceration of the stomach or duodenum, gastric adenocarcinomas and gastric lymphomas. Peptic ulcer treatment studies have shown that cure of
H. pylori
infection is associated with a dramatic reduction in the relapse rate of this usually chronic disease. Long term infection with
H. pylori
leads to the development of chronic atrophic gastritis, which has long been recognised as a precursor lesion in the development of gastric cancer. Thus a number of studies have now linked preceding
H. pylori
infection with an increased risk of developing gastric cancer. Therefore eradication of current infection and prevention of new infection with this organism has the potential to significantly reduce the incidence of diseases that result in considerable morbidity and mortalityl
1,2
.
Infection with
H. pylori
is difficult to treat. Current experimental therapies for treating the infection have problems with efficacy and significant levels of adverse effects. There are no prophylactic measures available. A solution to both the prevention and treatment of
H. pylori
infection would be the development of an immunogenic preparation that, as an immunotherapeutic, treated established infections, and as a vaccine, prevented the establishment of new or recurrent infections. Such a preparation would need to induce effective immune responses to protective antigens, while avoiding inducing responses to self antigens or other potentially harmful immune responses. This may be achieved by identifying the specific protective component or components and formulating immunotherapeutic or vaccine preparations including these component(s).
The identification of such protective components of an organism, is often accomplished through the use of an animal model of the infection. Initially,
H. pylori
did not naturally infect laboratory animals. However, an animal model of human
H. pylori
infection has been developed using a closely related organism,
H. felis
, and specific pathogen free (SPF) mice
3
. These organisms are able to colonise the gastric mucosa of SPF mice, where they establish a chronic infection with many of the features of
H. pylori
infection in humans.
H. felis
infection in the mice induces a chronic gastritis and a raised immune response. As in the human case, this response is not effective in curing the infection.
This model has been used to demonstrate that oral treatment of
H. felis
infected mice with a preparation containing disrupted
H. pylori
cells and cholera toxin as a mucosal adjuvant, can cure a significant portion of infected mice
4
. This effect is likely to be mediated through an immune response to a cross-reactive antigen possessed by each of the closely related species.
In working by the inventors leading to the present invention, these cross-reactive antigens were recognised by performing a Western blot using
H. pylori
disrupted cells as the antigen, and probing the blot with serum from mice immunised with
H. felis
and cholera toxin adjuvant. Sections of membrane containing proteins recognised as cross-reactive were removed from the membrane, the proteins bound to them were eluted, and their N-terminal amino acid sequence determined by microsequencing.
The N-terminal amino acid sequence of one of the two proteins that successfully yielded sequence data closely matched the previously published sequence of the microbial enzyme, urease
5
. This enzyme has already been shown to be a protective antigen when used in a vaccine to prevent infection.
The N-terminal amino acid sequence of the other protein closely matched the previously published N-terminal sequence of the microbial enzyme, catalase
6
. This enzyme has not previously been shown to be a protective antigen of
H. pylori.
International Patent Application No. PCT/FR95/00383 (Publication No. WO 95/27506) in the name Pasteur Merieux Serums et Vaccins, published Oct. 19, 1995, discloses an
H. pylori
immunising composition, based on proposed use of
H. pylori
catalase in substantially purified form as an immunising substance useful for prophylactic or therapeutic purposes. It is suggested that the catalase could be obtained either by extraction from
H. pylori
(using the purification method of Hazell et al.
10
) or by recombinant means. The disclosure contains no supporting data showing efficacy of
H. pylori
catalase in use as an immunising substance, nor is there any supporting disclosure or teaching of the preparation of
H. pylori
catalase by recombinant means or of the efficacy of recombinant catalase in use as an immunising substance.
Recently, an
H. pylori
(Sydney strain)/mouse model of human
H. pylori
infection has been developed and used by the present inventors to confirm that catalase, in particular recombinant catalase, has utility as a protective antigen.
SUMMARY OF THE INVENTION
In one aspect, the present invention provides an antigenic preparation for use in the treatment or prevention of Helicobacter infection, which comprises an at least partially purified preparation of the catalase of Helicobacter bacteria.
The term “at least partially purified” as used herein denotes a preparation in which the catalase content is greater, preferably at least 30% and more preferably at least 50% greater, than the catalase content of a whole cell sonicate of Helicobacter bacteria. Preferably, the preparation is one in which the catalase is “substantially pure”, that is one in which the catalase content is at least 80%, more preferably at least 90%, of the total Helicobacter antigens in the preparation.
Accordingly, in a particularly preferred embodiment, the present invention provides an antigenic preparation for use in treatment or prevention of Helicobacter infection, which comprises substantially pure catalase of Helicobacter bacteria. Such a preparation may be prepared as a recombinant catalase by techniques described hereinafter.
In another aspect, the present invention provides an isolated Helicobacter antigen for use in the treatment or prevention of Helicobacter infection in a mammalian host, which comprises the catalase of Helicobacter bacteria, or an immunogenic fragment thereof.
The term “isolated” as used herein denotes that the antigen has undergone at least one purification or isolation step, and preferably is in a form suitable for use in a vaccine composition.
It is to be understood that the present invention extends not only to an antigenic preparation or isolated antigen comprising the catalase of Helicobacter bacteria, but also to antigenic preparations comprising immunogenic fragments of this catalase, that is catalase fragments which are capable of eliciting a specific protective immune response in a mammalian host. Such immunogenic fragments may also be recognised by Helicobacter-specific antibodies, particularly monoclonal antibodies which have a protective or therapeutic effect in relation to Helicobacter infection or polyclonal antibodies contained in immune sera from mammalian hosts which have been vaccinated against Helicobacter infection.
In another aspect, the present invention provides a vaccine composition for use in the treatment or prevention of Helicobacter infection in a mammalian host, which comprises an immunologically effective amount of
Doidge Christopher V.
Hazell Stuart L.
Lee Adrian
Radcliff Flona J.
Foley & Lardner
Portner Ginny Allen
Smith Lynette R. F.
University of New South Wales
LandOfFree
Treatment and prevention of helicobacter infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment and prevention of helicobacter infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment and prevention of helicobacter infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3142128